
==== Front
Clin Hematol Int
Clin Hematol Int
3084
Clinical Hematology International
2590-0048
SAABRON PRESS Website: Clinical Hematology International

38817308
117026
10.46989/001c.117026
Perspective Article
How I treat newly diagnosed acute lymphoblastic leukemia
https://orcid.org/0000-0002-4827-4401
Sebastian Giebel Ph.D., M.D. 1
1 Bone Marrow Transplantation and Onco-Hematology Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch
Correspondence: Prof. Sebastian Giebel, Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch; 44-101 Gliwice, Str. Wybrzeze Armii Krajowej 15, Poland; tel. +48-322788523, fax +48-322789149, e.mail sgiebel@io.gliwice.pl
9 5 2024
2024
6 2 Impact of Best Practice Medicine 5161
15 5 2023
31 5 2023
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Treatment algorithms differ for adult patients with Philadelphia-negative (Ph-) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). For Ph- ALL intensive induction-consolidation chemotherapy using “pediatric-inspired” protocols is a standard of care. Allogeneic hematopoietic cell transplantation (allo-HCT) from either an HLA-matched sibling, unrelated or haploidentical donor should be considered for patients with high estimated risk of relapse. Inadequate response at the level of measurable residual disease (MRD) is the strongest adverse prognostic factor. Patients with B-ALL and detectable MRD should be treated with blinatumomab. In the future, the use of blinatumomab and/or inotuzumab ozogamycin in addition to first-line chemotherapy may become a new standard of care reducing the role of allo-HCT. For patients with Ph+ ALL, tyrosine kinase inhibitors (TKI) are the most important components of treatment protocols, while the intensity of chemotherapy may be reduced. Allo-HCT is recommended for all patients treated with imatinib along with low-intensity chemotherapy. Results of phase-II studies using front-line dasatinib or ponatinib in sequence or in combination with blinatumomab are very promising. Such a strategy may allow the avoidance of systemic chemotherapy. The future role of allo-HCT in this context appears uncertain.

acute lymphoblastic leukemia
induction
minimal residual disease
tyrosine kinase inhibitors
blinatumomab
inotuzumab ozogamycin
==== Body
pmcIntroduction

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease. According to the International Consensus Classification, more than 30 genetically defined subtypes of precursor lymphoid neoplasms may be distinguished and split into precursor B-cell neoplasms (B-cell acute lymphoblastic leukemia/lymphoma, B-ALL/LBL) and precursor T-cell neoplasms (T-cell acute lymphoblastic leukemia/lymphoma, T-ALL/LBL).1 At present, however, from the clinical point of view, only one subtype, i.e., Philadelphia chromosome-positive (Ph+) ALL, characterized by the presence of a t(9;22)(q34.1;q11.2) and corresponding BCR-ABL1 gene rearrangement requires particular treatment, while for the remaining ones (Philadelphia-negative, Ph- ALL) the first-line therapy is relatively consistent.

The treatment of adults with ALL traditionally consists of polychemotherapy. It includes several phases: a pre-treatment phase, mainly using glucocorticoids, followed by an induction phase, aimed at achieving complete remission (CR), and a consolidation phase to perpetuate the state of CR. Follow-up is either maintenance therapy or an allogeneic hematopoietic cell transplantation (allo-HCT), which is recommended for patients with a high estimated risk of disease recurrence.

In the 21st century, Ph+ and Ph- ALL treatment algorithms evolved differently. With the introduction of tyrosine kinase inhibitors (TKI), the treatment results for Ph+ ALL markedly improved. TKI became a backbone, while the intensity of chemotherapy tended to decrease. In contrast, for Ph-, there was a trend to escalate the intensity of chemotherapy following the pediatric experience. The use of so-called pediatric-inspired regimens (PIR) became a common practice, especially among adolescents and young adults (AYA). However, the definition of PIR and the upper age limit for AYA have not been well defined.

First-line treatment of Ph- ALL: current status

For patients with Ph- ALL, PIR is a standard of care. A meta-analysis of 25 studies comparing the results of pediatric protocols with those originally designed for adults showed an approximately 20% overall survival advantage at 5 years in favor of the pediatric ones in AYA.2 Direct implementation of pediatric protocols may be considered for patients up to 40 years old. The treatment intensity should be tapered for individuals between 40 and 55 years old. For those aged 55 years or more, the therapy should be personalized and adjusted to the performance status and comorbidities.

Details of the first-line treatment protocols differ among countries and study groups. The pre-treatment phase is usually based on glucocorticosteroids, mainly dexamethasone +/- cyclophosphamide (CP), administered for 5-7 days. After the initial reduction of the tumor burden, induction therapy is initiated, usually consisting of anthracyclines, vincristine (VCR), dexamethasone, and asparaginase. It may be followed by a second course, including CP, cytosine arabinoside (AraC), mercaptopurine, and methotrexate (MTX). CR is achieved in approximately 90% of patients.3 It is defined as bone marrow blasts < 5%, absence of blasts in the peripheral blood, absence of extramedullary disease, absolute neutrophil count > 1x109/L, platelet count > 100x109/L, and independence of red blood cell transfusions.4 The reasons for treatment failure include primary resistance or early death due to treatment complications, both affecting approximately 5% of patients.3 The consolidation phase includes alternating courses of chemotherapy, consisting of high doses (HD) of MTX, HD-AraC, CP, etoposide, asparaginase, and dexamethasone. The treatment algorithm may include a re-induction phase, i.e., a repeated course of the drugs used during initial induction. Repeated administration of high doses of polyethylene glycol (PEG)-asparaginase (2000 IU/m2) is a feature of PIR.5 Although the drug appears critical to increasing the overall treatment efficacy, it is associated with a substantial risk of severe complications, including thrombotic events, hepatotoxicity, and pancreatitis.6 The incidence of liver toxicity is higher in adults than in children.7 While the induction phase usually lasts 4-8 weeks, the consolidation phase takes approximately 6 months. Either maintenance or allo-HCT follows the consolidation phase. Maintenance lasts up to 2 years and includes mercaptopurine, MTX, vincristine, and glucocorticosteroids.

In parallel to systemic chemotherapy, intrathecal use of cytostatics, usually MTX, AraC, and dexamethasone, is obligatory to prevent relapse in the central nervous system (CNS). The same drugs are used to treat initial CNS involvement, if present. In addition, HD-MTX (usually 3 g/m2) administered during consolidation penetrates the blood-brain barrier and contributes to protection from CNS recurrence.8

Allo-HCT effectively prevents relapse in ALL adults, combining the conditioning regimen’s anti-leukemic activity and beneficial graft-versus-leukemia reaction mediated by donor-derived immune cells. Unfortunately, it is associated with a significant risk of non-relapse mortality (NRM) affecting 15-22% of patients, depending on the donor type.9 Therefore, Ph- ALL allo-HCT in the first CR is considered only for patients with a high estimated risk of relapse. Precise indications vary among study groups.10 The most commonly accepted high-risk feature is an inadequate response to induction, detected as measurable residual disease (MRD) or MRD persistence/recurrence after consolidation. MRD can be evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) to detect specific Ig/TCR gene rearrangements, or by multiparametric flow cytometry to detect leukemia-specific phenotypes.11 RQ-PCR is more expensive and time-consuming but associated with higher sensitivity (10-5), while flow cytometry is fast but less sensitive (10-4).12,13 The negative prognostic value of detectable MRD has been well-documented using both methods.14–18 The sensitivity level may further be increased by using digital droplet PCR or next-generation sequencing.19 The latter allows for the detection of ALL subclones. However, these methods have not been sufficiently standardized in ALL and, therefore, cannot be recommended for routine evaluation of MRD. Among other high-risk factors, most study groups consider high initial leukocyte count and adverse genetic subtypes, particularly KMT2A rearranged ALL.10

In recent years, immunotherapy appears increasingly important in addition to chemotherapy for adults with Ph- ALL. As demonstrated by the French study group, introducing an anti-CD20 antibody, rituximab, to all treatment phases for patients with CD20-positive ALL contributes to improved event-free survival (EFS) and reduced incidence of relapse.20 Such an effect could not be demonstrated by the UK study group that included all patients regardless of CD20 expression.21 In the latter study, rituximab was restricted to the induction phase. Although rituximab is not approved for treating ALL, several study groups included it in their treatment protocols.

Data from a retrospective propensity-score analysis by the MD Anderson Cancer Center (MDACC, Houston, USA) suggest improved results with ofatumumab, a fully human anti-CD20 monoclonal antibody, in combination with a hyper-CVAD (CP, VCR, doxorubicin, dexamethasone) protocol when compared to rituximab + hyper-CVAD. However, the differences in EFS and overall survival (OS) did not reach statistical significance.22

Blinatumomab, a bispecific anti-CD19/anti-CD3 T-cell enhancer, has been approved for treating patients in CR with MRD levels>10-3 in the bone marrow. As shown by the results of the phase II study, it may allow for the eradication of MRD in 78% of patients in the first or subsequent CR.23 It may be considered a bridge to allow HCT. However, the need for transplantation after blinatumomab remains controversial.

The use of modern PIR, incorporating all approved and available drugs, offers a chance of long-term survival to 50-70% of adults with Ph- ALL.24–34 Relapse and transplant-related mortality are the most frequent causes of treatment failure. The outcomes are inferior in older patients due to higher frequency of adverse molecular subtypes, poor tolerance of intensive chemotherapy and ineligibility for myeloablative allo-HCT.35 The current treatment algorithm for adults with Ph- ALL is shown in Fig. 1.

225398 Fig. 1. How do I treat newly diagnosed Ph-negative ALL in 2023?

R, rituximab; MRD, measurable residual disease; SR, standard risk; HR, high risk; allo-HCT, allogeneic hematopoietic cell transplantation

First-line treatment of Ph- ALL: perspectives

While in the first 2 decades of the 21st century the intensity of chemotherapy for patients with Ph- ALL tended to increase, this trend may reverse in view of results of modern studies incorporating immunotherapy to the first-line treatment. A series of phase-2 studies demonstrated feasibility of administration of either binatumomab, inotuzumab ozogamicin (InO, immunoconjugate of ani-CD22 monoclonal antibody and calicheamicin) or both, in combination or in sequence, with standard chemotherapy.36–39

In the GIMEMA LAL2317 trial, 2 courses of blinatumomab were administered, in addition to the standard induction-consolidation.36 Among 146 patients aged 18-65 years, the probabilities of OS and disease-free survival (DFS) at 12 months were 84% and 72%, respectively. In the French QUEST study, high risk patients, i.e. those presenting KMT2A-rearrangement, IKZF1 intragenic deletion, and/or MRD post-induction ≥10-4, received up to 5 cycles of blinatumomab during consolidation and maintenance phases, or as a bridge to allo-HCT.37 Among 94 evaluable individuals, the OS rate at 2.5 years was 79%, while the probability of DFS was 72%. In a study by Short et al., 45 patients aged 14-59 years were administered 4-7 cycles of blinatumomab +/- InO in addition to hyper-CVAD regimen.38 Three-year continuous remission and OS rates were 84% and 85%, respectively. Among those receiving InO, no relapses or NRM were observed at one year follow-up. Finally, in the ECOG-ACRIN E1910 phase-III trial, patients aged 30-70 years old who achieved CR with MRD <10-4 after induction and early intensification were randomly assigned to receive either standard chemotherapy or chemotherapy in sequence with 4 blocks of blinatumomab.39 The risk of mortality was significantly reduced in the blinatumomab arm (median OS: not reached versus 71.4 months; hazard ratio = 0.42, 95% CI: 0.24 - 0.75; p=0.003). These data strongly indicate that blinatumomab should be considered a standard of care in both MRD-positive and -negative disease status.

The use of immunotherapy in front-line treatment appears particularly attractive for older patients with Ph- B-ALL. Stelljes et al. reported results of the German phase-II trial where 45 patients with a median age of 64 years (range, 56-80 years) received induction based on InO combined with dexamethasone, followed by 2 courses of InO monotherapy, consolidation, reinduction and maintenance.40 The CR rate was 100%, while the probabilities of OS and EFS at 2 years were 81% and 73%, respectively. In the EWALL-INO study, 131 patients with a median age of 68 years (55-84) were induced with low doses of chemotherapy (VCR, CP, dexamethasone) including InO, followed by chemotherapy-based consolidation and maintenance.41 The OS and DFS rates at 2 years were 54% and 50%, respectively. In another prospective German study, 34 patients aged 65 (56-76) years were treated with induction, including idarubicin, VCR, and dexamethasone, followed by a single course of blinatumomab in sequence with chemotherapy.42 OS and DFS rates at 1 year were 84% and 89%, respectively. Overall, the results of the above-cited trials are much better than historical data with chemotherapy only, giving hope for a cure in older patients with Ph- B-ALL.43

T-ALL accounts for 20-25% of adult ALL. So far, humoral immunotherapy forms are unavailable for this disease subtype. Conventional chemotherapy remains a backbone, with attempts to personalize treatment by incorporating nelarabine in first-line protocols. In the UKALL14 trial, three doses of nelarabine were administered following the second phase of induction.44 This addition had no impact on any of the study outcomes. On the other hand, according to a retrospective analysis by MDACC, the use of nelarabine may contribute to improved outcomes in T-ALL subtypes other than early T-cell precursor ALL.45 Further prospective studies are needed to verify this finding.

Ph-like ALL is a disease subtype characterized by a gene expression profile similar to Ph+ ALL in the absence of BCR-ABL1 fusion gene.46 This subtype may be further subclassified according to the type of molecular alterations and affected pathways, and is associated with poor outcomes.47 ABL1 class mutations may be targeted by TKIs, like imatinib or dasatinib. JAK2 fusions, EPOR rearrangements, and activating JAK-STAT mutations are potentially sensitive to the JAK2 inhibitor ruxolitinib.48 The use of these agents in first-line treatment is under clinical investigation. So far, however, data on adults are scarce. Furthermore, the identification of Ph-like ALL is not routine clinical practice.

Perspectives for treating adults with Ph- ALL are presented in Fig. 2.

225399 Fig. 2. How would I like to treat newly diagnosed Ph-negative ALL?

BCP-ALL, B-cell precursor acute lymphoblastic leukemia; TCP-ALL, T-cell precursor acute lymphoblastic leukemia; InO, inotuzumab ozogamycin; MRD, measurable residual disease; SR, standard risk; HR, high risk; allo-HCT, allogeneic hematopoietic cell transplantation

First-line treatment of Ph+ ALL: current status

Ph+ ALL is the most common molecular subtype. Its frequency increases with age, being 5-15% in adolescents, 25-30% in patients aged 25-35 years and more than 35-40% in patients older than 35 years.49,50 Historically, Ph+ ALL was associated with a dismal prognosis, and considered a very high-risk subtype. Results improved dramatically with the introduction of TKIs.51,52 So far, imatinib is the only TKI approved for use in first-line treatment. The combination of imatinib with either corticosteroids or multi-agent chemotherapy results in 90-100% CR rate.53–56 Unfortunately, without subsequent allo-HCT most patients experience relapse. The role of intensity of concomitant chemotherapy was addressed in the GRAAPH-2005 study.57 Patients were randomly assigned to receive induction consisting of either imatinib in combination with vincristine and dexamethasone or imatinib + hyper-CVAD. CR rates were 98.5% and 91% (p=0.006), respectively, with increased early mortality observed in the hyper-CVAD arm. The 5-year EFS and OS rates were higher for the “low-intensity” arm, although the differences were not significant. Allo-HCT was intended for all patients. A post-hoc analysis revealed improved outcomes for those having an HLA-matched sibling donor (MSD) or matched unrelated donor (MUD) and actually treated with allo-HCT compared to the remaining individuals. Based on results of that study the use of imatinib in combination with low intensity chemotherapy became a standard of care. It should be accompanied by intrathecal prophylaxis of CNS relapse, as well as high doses of methotrexate in consolidation. Allo-HCT is recommended for all eligible patients. Strict MRD monitoring, based on BCR-ABL1 transcript detection, is obligatory. Persistence or recurrence of MRD may implicate the introduction of a second (dasatinib) or third (ponatinib) generation TKI, optimally after verification of the presence of point mutations within the ABL1 kinase domain. The use of TKI is also recommended as a maintenance after allo-HCT. It may be introduced either prophylactically, regardless of MRD status, or as a pre-emptive approach, in case of MRD-positivity.58 Detailed guidelines have been elaborated by the European Society for Blood and Marrow Transplantation (EBMT).59

The current treatment standard for adults with Ph+ ALL is presented in Fig. 3.

225400 Fig. 3. How do I treat newly diagnosed Ph-positive ALL in 2023?

R, rituximab; allo-HCT, allogeneic hematopoietic cell transplantation; TKI, tyrosine kinase inhibitor; MRD, measurable residual disease

First-line treatment of Ph+ ALL: perspectives

The upfront use of second or third generation TKI may contribute to an increased rate of molecular responses. When combined with intensive chemotherapy and/or modern immunotherapy, there is a potential for cure without allo-HCT. The only prospective, randomized trial comparing imatinib and dasatinib administered in parallel to intensive chemotherapy was performed in the pediatric population.60 The use of dasatinib was associated with improved EFS (71% versus 49% at 4 years) and OS (88% versus 69% at 4 years), with reduced incidence of relapse, including CNS relapse. Dasatinib is the only TKI that crosses the blood-brain barrier.

In the adult population, only results of phase-II studies are available. The combination of dasatinib with hyper-CVAD led to 96% CR rate and 46% probability of the OS at 5 years, with only 17% of patients treated with allo-HCT.61 The outcomes appear even better for ponatinib used in parallel to hyper-CVAD: 98% CR, 67% EFS and 71% OS rates at 5 years, with 30% of patients treated with allo-HCT.62 In the older population (>55 years old) dasatinib combined with intermediate dose chemotherapy allowed for a 36% 5-year OS rate, while allo-HCT was applied to 10% of patients.63

An Italian group performed a study using dasatinib + dexamethasone in induction, followed by 2-5 cycles of blinatumomab and dasatinib maintenance.64 The CR rate was 98%, including 60% molecular responses. EFS and OS rates at 18 months were 88% and 95%, respectively. The treatment was free from systemic chemotherapy except for 38% of patients referred for allo-HCT. Jabbour et al. performed a study combining ponatinib and blinatumomab for up to 5 cycles with subsequent ponatinib maintenance.65 Among 40 patients with median age of 57 (20-83) years, 96% achieved CR, while the probability of OS at 2 years was 95%. Only one patient received allo-HCT in CR1.

Taken together, it seems that the use of second or third generation TKI in combination or in sequence with blinatumomab may markedly improve the prognosis of patients with Ph+ ALL, reducing the role of allo-HCT as part of the first-line treatment. However, longer follow-up is needed to draw final conclusions. The perspectives of the treatment of adults with Ph+ ALL are summarized in Fig. 4.

225401 Fig. 4. How would I like to treat newly diagnosed Ph-positive ALL?

MRD, measurable residual disease; allo-HCT, allogeneic hematopoietic cell transplantation

Allo-HCT in first-line treatment

Allo-HCT is currently recommended for high-risk patients with Ph- ALL and all patients with Ph+ ALL treated with upfront imatinib. The choice of potential donors is wide, including MSD, MUD, mismatched unrelated donors (MMUD) and haploidentical relatives. The intensity of conditioning may be adjusted to the recipient’s biological status, which means that almost all patients with indications for allo-HCT may be offered this procedure.

The impact of donor type on the results of allo-HCT in ALL was a subject of several retrospective analyses. In a study by the EBMT Acute Leukemia Working Party, no significant difference could be detected between transplantations from MUD, MMUD and haploidentical donors.66 In another study, allo-HCT from haploidentical donors was associated with increased non-relapse-mortality compared to MSD transplants which, however, was counterbalanced by a reduced risk of relapse.67 Hence, it seems that in terms of survival, all donor types may be considered equally valuable.

Studies focused on haploidentical transplantations showed better results for unmanipulated grafts with the use of post-transplant cyclophosphamide as a backbone of immunosuppression, compared to regimens based on anti-thymocyte globulin.68 Bone marrow, as compared to peripheral blood as a source of stem cells, was associated with improved OS and leukemia-free survival, mainly as a consequence of reduced risk of GVHD and non-relapse mortality.69 Finally, as shown by the EBMT, results of haploidentical transplantations for patients with ALL tend to improve over time.70

The outcome of allo-HCT may be affected by the type of conditioning regimen. Results from retrospective analyses indicated that the use of myeloablative total body irradiation (TBI) was associated with a reduced risk of relapse and improved survival, compared to chemotherapy-based regimens.9,71,72 These findings were confirmed by a global study on a pediatric population. The outcomes were significantly better for patients treated with TBI at a dose of 12 Gy combined with etoposide, than for those treated with thiotepa and fludarabine combined with either busulfan or treosulfan.73 On the other hand, a prospective study in adults indicated non-inferiority of busulfan + cyclophosphamide compared to TBI at a total dose of 9 Gy + cyclophosphamide.74 That study, however, was restricted to B-ALL with standard-risk cytogenetics. Therefore, the choice of TBI dose as well as chemotherapy counterpart may play a role. The use of anti-thymocyte globulin for patients with ALL is a matter of controversy, as results from large scale registry-based studies indicate reduced incidence of chronic GVHD but increased risk of relapse in both Ph- and Ph+ ALL75,76

CAR T-cells now and in future

Chimeric antigen receptor (CAR) T-cells are genetically engineered T lymphocytes able to recognize and destroy cancer cells. Two products representing autologous CAR T-cells, tisagenlecleucel and brexucaptagene autoleucel have been approved for the treatment of relapsed/refractory B-ALL.77,78 Such therapy could potentially be offered to patients in CR1 with detectable MRD. In this clinical situation, CAR T-cells would be a final treatment, allowing to avoid allo-HCT. Clinical studies exploring this concept are ongoing.

Multiple preclinical and clinical studies are being conducted with the aim to optimize CAR T-cell products in terms of both their efficacy and safety. Among others, this includes simultaneous or sequential targeting of two antigens, as well as the ability to switch-off and switch-on the expression of the CAR.79 Similarly, allogeneic CAR T-cells are being engineered, with the ogjective to simplify the logistics of the procedure.80 Taking into account its very high research and development potential, it can be hypothesized that, in the future, CAR T-cells will become a predominant treatment tool, and may substitute all other forms of systemic therapy.

Summary

For adults with Ph- ALL, conventional chemotherapy using PIR remains a standard of care. Allo-HCT from either MSD, MUD, MMUD or haploidentical donors should be considered for patients with high risk of relapse. Patients with B-ALL and detectable MRD should be treated with blinatumomab (Fig. 1). In the future, the use of blinatumomab and/or InO in addition to first-line chemotherapy may become a new standard of care reducing the role of allo-HCT (Fig. 2).

For patients with Ph+ ALL the use of TKI is a priority. Imatinib in combination with reduced-intensity chemotherapy, followed by allo-HCT is currently recommended (Fig. 3). Front-line dasatinib or ponatinib, in sequence or in combination with blinatumomab, is a promising strategy, which may allow to avoid systemic chemotherapy. The future role of allo-HCT in this context appears uncertain (**Fig. 4.

Competing Interests

Novartis (advisory boards, speakers bureau, honoraria), Gilead (advisory boards, speakers bureau, honoraria), Amgen (advisory boards, speakers bureau, honoraria), Pfizer (advisory boards, speakers bureau, honoraria), Roche (advisory boards, speakers bureau, honoraria), Angelini (advisory boards, speakers bureau, honoraria), Servier (speakers bureau, honoraria).
==== Refs
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data Blood Arber D. A. Orazi A. Hasserjian R. P. Borowitz M. J. Calvo K. R. Kvasnicka H. M. Wang S. A. Bagg A. Barbui T. Branford S. Bueso-Ramos C. E. Cortes J. E. Dal Cin P. DiNardo C. D. Dombret H. Duncavage E. J. Ebert B. L. Estey E. H. Facchetti F. Foucar K. Gangat N. Gianelli U. Godley L. A. Gökbuget N. Gotlib J. Hellström-Lindberg E. Hobbs G. S. Hoffman R. Jabbour E. J. Kiladjian J. J. Larson R. A. Le Beau M. M. Loh M. L. Löwenberg B. Macintyre E. Malcovati L. Mullighan C. G. Niemeyer C. Odenike O. M. Ogawa S. Orfao A. Papaemmanuil E. Passamonti F. Porkka K. Pui C. H. Radich J. P. Reiter A. Rozman M. Rudelius M. Savona M. R. Schiffer C. A. Schmitt-Graeff A. Shimamura A. Sierra J. Stock W. A. Stone R. M. Tallman M. S. Thiele J. Tien H. F. Tzankov A. Vannucchi A. M. Vyas P. Wei A. H. Weinberg O. K. Wierzbowska A. Cazzola M. Döhner H. Tefferi A. 2022
140 1200 1228 10.1182/blood.2022015850 10.1182/blood.2022015850 35767897
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review JAMA Oncol Siegel S. E. Stock W. Johnson R. H. Advani A. Muffly L. Douer D. Reed D. Lewis M. Freyer D. R. Shah B. Luger S. Hayes-Lattin B. Jaboin J. J. Coccia P. F. DeAngelo D. J. Seibel N. Bleyer A. 2018
4 725 734 10.1001/jamaoncol.2017.5305 10.1001/jamaoncol.2017.5305 29450465
Modern therapy of acute lymphoblastic leukemia J Clin Oncol Bassan R. Hoelzer D. 10 2 2011
29 5 532 543 10.1200/JCO.2010.30.1382 10.1200/JCO.2010.30.1382
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium Blood Buchmann S. Schrappe M. Baruchel A. Biondi A. Borowitz M. Campbell M. Cario G. Cazzaniga G. Escherich G. Harrison C.J. Heyman M. Hunger S.P. Kiss C. Liu H.C. Locatelli F. Loh M.L. Manabe A. Mann G. Pieters R. Pui C.H. Rives S. Schmiegelow K. Silverman L.B. Stary J. Vora A. Brown P. 2022
139 1785 1793 10.1182/blood.2021012328 10.1182/blood.2021012328 34192312
Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review Blood Lymphat Cancer Bender C. Maese L. Carter-Febres M. Verma A. 2021
11 25 40 10.2147/BLCTT.S245210 10.2147/BLCTT.S245210 33907490
Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group Pol Arch Med Wewn Piatkowska-Jakubas B. Krawczyk-Kuliś M. Giebel S. Adamczyk-Cioch M. Czyz A. Lech Marańda E. Paluszewska M. Pałynyczko G. Piszcz J. Hołowiecki J. Polish Adult Leukemia Group 2008
118 664 669 10.20452/pamw.518 19140571
Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia Blood Rev Douer D. Gokbuget N. Stock W. Boissel N. 2022
53 100908 10.1016/j.blre.2021.100908 10.1016/j.blre.2021.100908 35031177
Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group Pol Arch Med Wewn Giebel S. Krawczyk-Kuliś M. Adamczyk-Cioch M. Czyz A. Lech-Marańda E. Piatkowska-Jakubas B. Paluszewska M. Pałynyczko G. Piszcz J. Hołowiecki J. Polish Adult Leukemia Group 2008
118 Jun 356 361 10.20452/pamw.414 18619191
Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Haematologica Giebel S. Labopin M. Socié G. Beelen D. Browne P. Volin L. Kyrcz-Krzemien S. Yakoub-Agha I. Aljurf M. Wu D. Michallet M. Arnold R. Mohty M. Nagler A. 2017
102 139 149 10.3324/haematol.2016.145631 10.3324/haematol.2016.145631 27686376
Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant Giebel S. Marks D. I. Boissel N. Baron F. Chiaretti S. Ciceri F. Cornelissen J. J. Doubek M. Esteve J. Fielding A. Foa R. Gorin N. C. Gökbuget N. Hallböök H. Hoelzer D. Paravichnikova E. Ribera J. M. Savani B. Rijneveld A. W. Schmid C. Wartiovaara-Kautto U. Mohty M. Nagler A. Dombret H. 2019
54 10 798 809 10.1038/s41409-018-0373-4 10.1038/s41409-018-0373-4
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia Szczepański T. 2007
21 622 626 10.1038/sj.leu.2404603 17301806
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies Blood van Dongen J.J. van der Velden V.H. Brüggemann M. Orfao A. 2015
125 3996 4009 10.1182/blood-2015-03-580027 10.1182/blood-2015-03-580027 25999452
B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model Am J Clin Pathol Shaver A. C. Greig B. W. Mosse C. A. Seegmiller A. C. 2015
143 716 724 10.1309/AJCPOOJRAVUN75GD 10.1309/AJCPOOJRAVUN75GD 25873506
Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study Br J Haematol Holowiecki J. Krawczyk-Kulis M. Giebel S. Jagoda K. Stella-Holowiecka B. Piatkowska-Jakubas B. Paluszewska M. Seferynska I. Lewandowski K. Kielbinski M. Czyz A. Balana-Nowak A. Król M. Skotnicki A. B. Jedrzejczak W. W. Warzocha K. Lange A. Hellmann A. 2008
142 227 237 10.1111/j.1365-2141.2008.07185.x 10.1111/j.1365-2141.2008.07185.x
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia Blood Bruggemann M. Raff T. Flohr T. Gökbuget N. Nakao M. Droese J. Lüschen S. Pott C. Ritgen M. Scheuring U. Horst H.A. Thiel E. Hoelzer D. Bartram C.R. Kneba M. German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia 2006
107 1116 1123 10.1182/blood-2005-07-2708 10.1182/blood-2005-07-2708 16195338
Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia J Clin Oncol Mortuza F. Y. Papaioannou M. Moreira I. M. Coyle L. A. Gameiro P. Gandini D. Prentice H. G. Goldstone A. Hoffbrand A. V. Foroni L. 2002
20 4 1094 1104 10.1200/JCO.2002.20.4.1094 10.1200/JCO.2002.20.4.1094 11844835
Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value Blood Vidriales M. B. Perez J. J. Lopez-Berges M. C. Gutiérrez N. Ciudad J. Lucio P. Vazquez L. García-Sanz R. del Cañizo M. C. Fernández-Calvo J. Ramos F. Rodríguez M. J. Calmuntia M. J. Porwith A. Orfao A. San-Miguel J. F. 2003
101 4695 4700 10.1182/blood-2002-08-2613 10.1182/blood-2002-08-2613 12586618
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia Hematology Gokbuget N. Dombret H. Giebel S. Bruggemann M. Doubek M. Foà R. Hoelzer D. Kim C. Martinelli G. Parovichnikova E. Rambaldi A. Ribera J.M. Schoonen M. Stieglmaier J.M. Zugmaier G. Bassan R. 2019
24 337 348 10.1080/16078454.2019.1567654 10.1080/16078454.2019.1567654 30757960
Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia Cancers (Basel) Starza Della I. De Novi L. A. Elia L. Bellomarino V. Beldinanzi M. Soscia R. Cardinali D. Chiaretti S. Guarini A. Foà R. 2023
15 374 10.3390/cancers15020374 10.3390/cancers15020374 36672325
Addition of Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia N Engl J Med Maury S. Chevret S. Thomas X. Heim D. Leguay T. Huguet F. Chevallier P. Hunault M. Boissel N. Escoffre-Barbe M. Hess U. Vey N. Pignon J. M. Braun T. Marolleau J. P. Cahn J. Y. Chalandon Y. Lhéritier V. Beldjord K. Béné M. C. Ifrah N. Dombret H. 2016
375 1044 1053 10.1056/NEJMoa1605085 10.1056/NEJMoa1605085 27626518
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial Lancet Haematol Marks D. I. Kirkwood A. A. Rowntree C. J. Aguiar M. Bailey K. E. Beaton B. Cahalin P. Castleton A. Z. Clifton-Hadley L. Copland M. Goldstone A. H. Kelly R. Lawrie E. Lee S. McMillan A. K. McMullin M. F. Menne T. F. Mitchell R. J. Moorman A. V. Patel B. Patrick P. Smith P. Taussig D. Yallop D. Alapi K. Z. Fielding A. K. 2022
9 e262 e275 10.1016/S2352-3026(22)00038-2 10.1016/S2352-3026(22)00038-2 35358441
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis Cancer Sasaki K. Kantarjian H. M. Morita K. Short N. J. Konopleva M. Jain N. Ravandi F. Garcia-Manero G. Wang S. Khoury J. D. Jorgensen J. L. Champlin R. E. Khouri I. F. Kebriaei P. Schroeder H. M. Khouri M. Garris R. Takahashi K. O'Brien S. M. Jabbour E. J. 2021
127 3381 3389 10.1002/cncr.33655 10.1002/cncr.33655 34138471
Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia Blood Gokbuget N. Dombret H. Bonifacio M. Reichle A. Graux C. Faul C. Diedrich H. Topp M. S. Brüggemann M. Horst H. A. Havelange V. Stieglmaier J. Wessels H. Haddad V. Benjamin J. E. Zugmaier G. Nagorsen D. Bargou R. C. 2018
131 1522 1531 10.1182/blood-2017-08-798322 10.1182/blood-2017-08-798322 29358182
National PEGASPARGASE-modified risk-oriented program for Philadelphia-negative adult acute lymphoblastic leukemia/lymphoblastic lymphoma (PH-ALL/LL). GIMEMA LAL 1913 final results HemaSphere Bassan R. Chiaretti S. Della Starza I. Spinelli O. Santoro A. Elia L. De Propris M. S. Scattolin A. M. Paoloni F. Messina M. Audisio E. Marbello L. Borlenghi M. Zappasodi P. Vetro C. Martinelli G. Mattei D. Fracchiolla N. Bocchia M. De Fabritiis P. Bonifacio M. Candoni A. Cassibba V. Di Bartolomeo P. Latte G. Trappolini S. Guarini A. Vitale A. Fazi P. Vignetti M. Rambaldi A. Foà R. 2022
6 S3 29 10.1097/01.HS9.0000843348.46426.e0
First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL) Blood Gökbuget N. Stelljes M. Viardot A. Nachtkamp K. Steffen B. 2021
138 25 362 10.1182/blood-2021-146306
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial J Clin Oncol Huguet F. Chevret S. Leguay T. Thomas X. Boissel N. Escoffre-Barbe M. Chevallier P. Hunault M. Vey N. Bonmati C. Lepretre S. Marolleau J.P. Pabst T. Rousselot P. Buzyn A. Cahn J.Y. Lhéritier V. Béné M.C. Asnafi V. Delabesse E. Macintyre E. Chalandon Y. Ifrah N. Dombret H. 2018
36 2514 2523 10.1200/JCO.2017.76.8192 10.1200/JCO.2017.76.8192
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial Blood Adv Rijneveld A. W. van der Holt B. de Weerdt O. Biemond B. J. van de Loosdrecht A. A. van der Wagen L. E. Bellido M. van Gelder M. van der Velden W. J. F. M. Selleslag D. van Lammeren-Venema D. Halkes C. J. M. Fijnheer R. Havelange V. van Sluis G. L. Legdeur M. C. Deeren D. Gadisseur A. Sinnige H. A. M. Breems D. A. Jaspers A. Legrand O. Terpstra W. E. Boersma R. S. Mazure D. Triffet A. Tick L. W. Beel K. Maertens J. A. Beverloo H. B. Bakkus M. Homburg C. H. E. de Haas V. van der Velden V. H. J. Cornelissen J. J. 2022
6 1115 1125 10.1182/bloodadvances.2021005624 10.1182/bloodadvances.2021005624 34883506
High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG Leukemia Sakura T. Hayakawa F. Sugiura I. Murayama T. Imai K. Usui N. Fujisawa S. Yamauchi T. Yujiri T. Kakihana K. Ito Y. Kanamori H. Ueda Y. Miyata Y. Kurokawa M. Asou N. Ohnishi K. Ohtake S. Kobayashi Y. Matsuo K. Kiyoi H. Miyazaki Y. Naoe T. 2018
32 626 632 10.1038/leu.2017.283 10.1038/leu.2017.283 28914260
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen Am J Hematol Rytting M. E. Jabbour E. J. Jorgensen J. L. Ravandi F. Franklin A. R. Kadia T. M. Pemmaraju N. Daver N. G. Ferrajoli A. Garcia-Manero G. Konopleva M. Y. Borthakur G. Garris R. Wang S. Pierce S. Schroeder K. Kornblau S. M. Thomas D. A. Cortes J. E. O'Brien S. M. Kantarjian H. M. 2016
91 819 823 10.1002/ajh.24419 10.1002/ajh.24419 27178680
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07 Blood Cancer Journal Bassan R. Pavoni C. Intermesoli T. Spinelli O. Tosi M. Audisio E. Marmont F. Cattaneo C. Borlenghi E. Cortelazzo S. Cavattoni I. Fumagalli M. Mattei D. Romani C. Cortelezzi A. Fracchiolla N. Ciceri F. Bernardi M. Scattolin A. M. Depaoli L. Masciulli A. Oldani E. Rambaldi A. 2020
10 119 10.1038/s41408-020-00383-2 10.1038/s41408-020-00383-2 33188164
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia Leukemia Toft N. Birgens H. Abrahamsson J. Griškevičius L. Hallböök H. Heyman M. Klausen T. W. Jónsson Ó. G. Palk K. Pruunsild K. Quist-Paulsen P. Vaitkeviciene G. Vettenranta K. Åsberg A. Frandsen T. L. Marquart H. V. Madsen H. O. Norén-Nyström U. Schmiegelow K. 2018
32 606 615 10.1111/ejh.12562 10.1111/ejh.12562
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia Blood Ribera J. M. Morgades M. Ciudad J. Montesinos P. Esteve J. Genescà E. Barba P. Ribera J. García-Cadenas I. Moreno M. J. Martínez-Carballeira D. Torrent A. Martínez-Sánchez P. Monsalvo S. Gil C. Tormo M. Artola M. T. Cervera M. González-Campos J. Rodríguez C. Bermúdez A. Novo A. Soria B. Coll R. Amigo M. L. López-Martínez A. Fernández-Martín R. Serrano J. Mercadal S. Cladera A. Giménez-Conca A. Peñarrubia M. J. Abella E. Vall-Llovera F. Hernández-Rivas J. M. Garcia-Guiñon A. Bergua J. M. de Rueda B. Sánchez-Sánchez M. J. Serrano A. Calbacho M. Alonso N. Méndez-Sánchez J. Á. García-Boyero R. Olivares M. Barrena S. Zamora L. Granada I. Lhermitte L. Feliu E. Orfao A. 2021
137 1879 1894 10.1182/blood.2020007311 10.1182/blood.2020007311 33150388
Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003 Br J Haematol Hough R. Rowntree C. Goulden N. Mitchell C. Moorman A. Wade R. Vora A. 2016
172 439 451 10.1111/bjh.13847 10.1111/bjh.13847
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 Blood Stock W. Luger S. M. Advani A. S. Yin J. Harvey R. C. Mullighan C. G. Willman C. L. Fulton N. Laumann K. M. Malnassy G. Paietta E. Parker E. Geyer S. Mrózek K. Bloomfield C. D. Sanford B. Marcucci G. Liedtke M. Claxton D. F. Foster M. C. Bogart J. A. Grecula J. C. Appelbaum F. R. Erba H. Litzow M. R. Tallman M. S. Stone R. M. Larson R. A. 2019
133 1548 1559 10.1182/blood-2018-10-881961 10.1182/blood-2018-10-881961
Management of acute lymphoblastic leukemia in older adults Clin Adv Hematol Oncol Jammal N. Kantarjian H.M. Haddad F. Jabbour E.J. 2022
20 161 168 36607346
Preliminary results of the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial for newly diagnosed adult Ph-negative B-lineage ALL patients HemaSphere Bassan R. Chiaretti S. Della Starza I. Spinelli O. Santoro A. Elia L. Vitale A. Taherinasab A. Piccini M. Ferrara F. Sica S. Zappasodi P. Borlenghi E. Bocchia M. Califano C. Di Raimondo F. Pane F. Candoni A. Ruggeri M. Audisio E. Lunghi M. Mianulli A.M. Messina M. Marino M.R. Arena V. Rambaldi A. Foà R. 2021
5 S2 8
Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study Blood Boissel N. Huguet F. Leguay T. Hunault M. Kim R.. 2022
140 507 509 10.1182/blood-2022-159397
Hyper-CVAD with sequential blinatumomab, with or without inotuzumab ozogamycin, in adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia Hemasphere Short N. Kantarjian H. Ravandi F. Yilmaz M. Kadia T. Thompson P. Huang H. Konopleva M. Ferrajoli A. Jain N. Sasaki K. Alvarado Y. Borthakur G. Dinardo C. Ohanian M. Macaron W. Kornblau S. Zhao M. Kwari M. Loiselle C. Delumpa R. Milton A. Rivera J. Lewis S. Garris R. Jabbour E. 2022
6 S3 540 10.1097/01.HS9.0000844372.43459.d0
Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial Blood Litzow M. Sun Z. Paietta E. Mattison R. J. 2022
140 39 LBA 1 10.1182/blood-2022-171751
Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) Blood Stelljes M. Alakel N. Wäsch R. Scholl S. 2022
140 510 512 10.1182/blood-2022-162235
Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study Blood Chevallier P. Leguay T. Kim R. Delord M.. 2022
140 6114 6116 10.1182/blood-2022-166035
Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial Blood Gökbuget N. Stoltefuß A. Topp M. S. Schwartz S.. 2021
138 42 3399 10.1182/blood-2021-146214
Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience Ann Hematol Robak T. Szmigielska-Kapłon A. Wrzesień-Kuś A. Wierzbowska A. Skotnicki A. B. Piatkowska-Jakubas B. Kuliczkowski K. Mazur G. Zduńczyk A. Stella-Hołowiecka B. Hołowiecki J. Dwilewicz-Trojaczek J. Madry K. Dmoszyńska A. Cioch M. 2004
83 225 231 10.1007/s00277-003-0808-9 10.1007/s00277-003-0808-9 14648030
First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006) Blood Rowntree C. J. Kirkwood A. A. Clifton-Hadley L. Farah N. Mansour M. R.. 2021
138 366 10.1182/blood-2021-152355
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine Am J Hematol Morita K. Jain N. Kantarjian H. akahashi K. Fang H. Konopleva M. El Hussein S. Wang F. Short N.J. Maiti A. Sasaki K. Garcia-Manero G. Konoplev S. Ravandi F. Khoury J.D. Jabbour E. 2021
96 589 598 10.1002/ajh.26144 10.1002/ajh.26144 33639000
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study The Lancet Oncology Den Boer M. L. van Slegtenhorst M. De Menezes R. X. Cheok M. H. Buijs-Gladdines J. G. Peters S. T. Van Zutven L. J. Beverloo H. B. Van der Spek P. J. Escherich G. Horstmann M. A. Janka-Schaub G. E. Kamps W. A. Evans W. E. Pieters R. 2009
10 125 134 10.1016/S1470-2045(08)70339-5 10.1016/S1470-2045(08)70339-5 19138562
The biology of Philadelphia chromosome-like ALL Best Pract Res Clin Haematol Roberts K. G. 2017
30 212 221 10.1016/j.beha.2017.07.003 10.1016/j.beha.2017.07.003 29050694
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia New Engl J Med Roberts K. G. Li Y. Payne-Turner D. Yang Y. L. Pei D. McCastlain K. Ding L. Lu C. Song G. Ma J. Becksfort J. Rusch M. Chen S. C. Easton J. Cheng J. Boggs K. Santiago-Morales N. Iacobucci I. Fulton R. S. Wen J. Valentine M. Cheng C. Paugh S. W. Devidas M. Chen I. M. Reshmi S. Smith A. Hedlund E. Gupta P. Nagahawatte P. Wu G. Chen X. Yergeau D. Vadodaria B. Mulder H. Winick N. J. Larsen E. C. Carroll W. L. Heerema N. A. Carroll A. J. Grayson G. Tasian S. K. Moore A. S. Keller F. Frei-Jones M. Whitlock J. A. Raetz E. A. White D. L. Hughes T. P. Guidry Auvil A. Smith M. A. Marcucci G. Bloomfield C. D. Mrózek K. Kohlschmidt J. Stock W. Kornblau S. M. Konopleva M. Paietta E. Pui C. H. Jeha S. Relling M. V. Evans W. E. Gerhard D. S. Gastier-Foster J. M. Mardis E. Wilson R. K. Loh M. L. Downing J. R. Hunger S. P. Willman C. L. Zhang J. Mullighan C. G. 2014
371 1005 1015 10.1056/NEJMoa1403088 10.1056/NEJMoa1403088 25207766
Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group Blood Burmeister T. Schwartz S. Bartram C.R. Gökbuget N. Hoelzer D. Thiel E. GMALL study group 2008
112 918 919 10.1182/blood-2008-04-149286 10.1182/blood-2008-04-149286
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial Blood Moorman A. V. Harrison C. J. Buck G. A. Richards S. M. Secker-Walker L. M. Martineau M. Vance G. H. Cherry A. M. Higgins R. R. Fielding A. K. Foroni L. Paietta E. Tallman M. S. Litzow M. R. Wiernik P. H. Rowe J. M. Goldstone A. H. Dewald G. W. Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute 2007
109 50 3189 3197 10.1182/blood-2006-10-051912 10.1182/blood-2006-10-051912
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood Thomas D.A. Faderl S. Cortes J. O'Brien S. Giles F.J. Kornblau S.M. Garcia-Manero G. Keating M.J. Andreeff M. Jeha S. Beran M. Verstovsek S. Pierce S. Letvak L. Salvado A. Champlin R. Talpaz M. Kantarjian H. 2004
103 4396 407 10.1182/blood-2003-08-2958 10.1182/blood-2003-08-2958 14551133
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study Blood de Labarthe A. Rousselot P. Huguet-Rigal F. Delabesse E. Witz F. Maury S. Réa D. Cayuela J. M. Vekemans M. C. Reman O. Buzyn A. Pigneux A. Escoffre M. Chalandon Y. MacIntyre E. Lhéritier V. Vernant J. P. Thomas X. Ifrah N. Dombret H. Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) 2007
109 1408 1413 10.1182/blood-2006-03-011908 10.1182/blood-2006-03-011908
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood Wassmann B. Pfeifer H. Goekbuget N. Beelen D. W. Beck J. Stelljes M. Bornhäuser M. Reichle A. Perz J. Haas R. Ganser A. Schmid M. Kanz L. Lenz G. Kaufmann M. Binckebanck A. Brück P. Reutzel R. Gschaidmeier H. Schwartz S. Hoelzer D. Ottmann O. G. 2006
108 1469 1477 10.1182/blood-2005-11-4386 10.1182/blood-2005-11-4386 16638934
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy Br J Haematol Yanada M. Sugiura I. Takeuchi J. Akiyama H. Maruta A. Ueda Y. Usui N. Yagasaki F. Yujiri T. Takeuchi M. Nishii K. Kimura Y. Miyawaki S. Narimatsu H. Miyazaki Y. Ohtake S. Jinnai I. Matsuo K. Naoe T. Ohno R. Japan Adult Leukemia Study Group 2008
143 503 510 10.1111/j.1365-2141.2008.07377.x 10.1111/j.1365-2141.2008.07377.x 18986386
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial Haematologica Ribera J. M. Oriol A. Gonzalez M. Vidriales B. Brunet S. Esteve J. Del Potro E. Rivas C. Moreno M. J. Tormo M. Martín-Reina V. Sarrá J. Parody R. de Oteyza J. P. Bureo E. Bernal M. T. 2010
95 87 95 10.3324/haematol.2009.011221 10.3324/haematol.2009.011221 19797728
Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL positive acute lymphoblastic leukemia Leukemia Mizuta S. Matsuo K. Yagasaki F. Yujiri T. Hatta Y. Kimura Y. Ueda Y. Kanamori H. Usui N. Akiyama H. Miyazaki Y. Ohtake S. Atsuta Y. Sakamaki H. Kawa K. Morishima Y. Ohnishi K. Naoe T. Ohno R. 2011
25 41 47 10.1038/leu.2010.228 10.1038/leu.2010.228 20944676
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia Blood Chalandon Y. Thomas X. Hayette S. Cayuela J. M. Abbal C. Huguet F. Raffoux E. Leguay T. Rousselot P. Lepretre S. Escoffre-Barbe M. Maury S. Berthon C. Tavernier E. Lambert J. F. Lafage-Pochitaloff M. Lhéritier V. Chevret S. Ifrah N. Dombret H. 2015
125 3711 3719 10.1182/blood-2015-02-627935 10.1182/blood-2015-02-627935 25878120
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia Leukemia Pfeifer H. Wassmann B. Bethge W. Dengler J. Bornhäuser M. Stadler M. Beelen D. Vucinic V. Burmeister T. Stelljes M. Faul C. Dreger P. Kiani A. Schäfer-Eckart K. Schwerdtfeger R. Lange E. Kubuschok B. Horst H.A. Gramatzki M. Brück P. Serve H. Hoelzer D. Gökbuget N. Ottmann O.G. GMALL Study Group 2013
27 1254 1262 10.1038/leu.2012.352 10.1038/leu.2012.352 23212150
Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Cancer Giebel S. Czyz A. Ottmann O. Baron F. Brissot E. Ciceri F. Cornelissen J. J. Esteve J. Gorin N. C. Savani B. Schmid C. Mohty M. Nagler A. 2016
122 2941 2951 10.1002/cncr.30130 10.1002/cncr.30130 27309127
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial JAMA Oncol Shen S. Chen X. Cai J. Yu J. Gao J. Hu S. Zhai X. Liang C. Ju X. Jiang H. Jin R. Wu X. Wang N. Tian X. Pan K. Jiang H. Sun L. Fang Y. Li C.K. Hu Q. Yang M. Zhu Y. Zhang H. Li C. Pei D. Jeha S. Yang J.J. Cheng C. Tang J. Zhu X. Pui C.H. 2020
6 358 366 10.1001/jamaoncol.2019.5868 10.1001/jamaoncol.2019.5868 31944221
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia Cancer Ravandi F. O'Brien S. M. Cortes J. E. Thomas D. M. Garris R. Faderl S. Burger J. A. Rytting M. E. Ferrajoli A. Wierda W. G. Verstovsek S. Champlin R. Kebriaei P. McCue D. A. Huang X. Jabbour E. Garcia-Manero G. Estrov Z. Kantarjian H. M. 2015
121 4158 4164 10.1002/cncr.29646 10.1002/cncr.29646 26308885
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia Clin Lymphoma Myeloma Leuk Jabbour E. DerSarkissian M. Duh M. S. McCormick N. Cheng W. Y. McGarry L. J. Souroutzidis A. Huang H. O'Brien S. Ravandi F. Kantarjian H. M. 2018
18 257 265 10.1016/j.clml.2018.02.010 10.1016/j.clml.2018.02.010 29519619
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL Blood Rousselot P. Coude M. M. Gokbuget N. Gambacorti Passerini C. Hayette S. Cayuela J. M. Huguet F. Leguay T. Chevallier P. Salanoubat C. Bonmati C. Alexis M. Hunault M. Glaisner S. Agape P. Berthou C. Jourdan E. Fernandes J. Sutton L. Banos A. Reman O. Lioure B. Thomas X. Ifrah N. Lafage-Pochitaloff M. Bornand A. Morisset L. Robin V. Pfeifer H. Delannoy A. Ribera J. Bassan R. Delord M. Hoelzer D. Dombret H. Ottmann O. G. European Working Group on Adult ALL (EWALL) group 2016
128 774 782 10.1182/blood-2016-02-700153 10.1182/blood-2016-02-700153 27121472
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults N Engl J Med Foà R. Bassan R. Vitale A. Elia L. Piciocchi A. Puzzolo M.C. Canichella M. Viero P. Ferrara F. Lunghi M. Fabbiano F. Bonifacio M. Fracchiolla N. Di Bartolomeo P. Mancino A. De Propris M.S. Vignetti M. Guarini A. Rambaldi A. Chiaretti S. GIMEMA Investigators 2020
383 1613 1623 10.1056/NEJMoa2016272 10.1056/NEJMoa2016272 33085860
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial Lancet Haematol Jabbour E. Short N. J. Jain N. Huang X. Montalban-Bravo G. Banerjee P. Rezvani K. Jiang X. Kim K. H. Kanagal-Shamanna R. Khoury J. D. Patel K. Kadia T. M. Daver N. Chien K. Alvarado Y. Garcia-Manero G. Issa G. C. Haddad F. G. Kwari M. Thankachan J. Delumpa R. Macaron W. Garris R. Konopleva M. Ravandi F. Kantarjian H. 2023
10 e24 e34 10.1016/S2352-3026(22)00319-2 10.1016/S2352-3026(22)00319-2 36402146
Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT Leukemia Shem-Tov N. Peczynski C. Labopin M. Itälä-Remes M. Blaise D. Labussière-Wallet H. Socié G. Kröger N. Mielke S. Afanasyev B. Chevallier P. Tischer J. Helbig G. Jindra P. Peric Z. Giebel S. Mohty M. Nagler A. 2020
34 66 283 292 10.1038/s41375-019-0544-3 10.1038/s41375-019-0544-3 31427719
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation J Hematol Oncol Nagler A. Labopin M. Houhou M. Aljurf M. Mousavi A. Hamladji R. M. Al Zahrani M. Bondarenko S. Arat M. Angelucci E. Koc Y. Gülbas Z. Sica S. Bourhis J. H. Canaani J. Brissot E. Giebel S. Mohty M. 2021
14 53 10.1186/s13045-021-01065-7 10.1186/s13045-021-01065-7 33794963
Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia Haematologica Nagler A. Kanate A. S. Labopin M. Ciceri F. Angelucci E. Koc Y. Gülbas Z. Arcese W. Tischer J. Pioltelli P. Ozdogu H. Afanasyev B. Wu D. Arat M. Peric Z. Giebel S. Savani B. Mohty M. 2021
106 1591 1598 10.3324/haematol.2020.247296 10.3324/haematol.2020.247296 32354866
Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia Leukemia Nagler A. Dholaria B. Labopin M. Savani B. N. Angelucci E. Koc Y. Arat M. Pioltelli P. Sica S. Gülbas Z. Tischer J. Bernasconi P. Pavlu J. Socié G. Blaise D. Rigacci L. Martino M. Diez-Martin J. L. Perić Z. Giebel S. Mohty M. 2020
34 2766 2775 10.1038/s41375-020-0850-9 10.1038/s41375-020-0850-9 32393841
Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Cancer Nagler A. Labopin M. Koc Y. Angelucci E. Tischer J. Arat M. Pioltelli P. Bernasconi P. Chiusolo P. Diez-Martin J. L. Sanz J. Ciceri F. Peric Z. Giebel S. Canaani J. Mohty M. 2021
127 2507 2514 10.1002/cncr.33522 10.1002/cncr.33522 33739471
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT J Hematol Oncol Pavlů J. Labopin M. Niittyvuopio R. Socié G. Yakoub-Agha I. Wu D. Remenyi P. Passweg J. Beelen D.W. Aljurf M. Kröger N. Labussière-Wallet H. Perić Z. Giebel S. Nagler A. Mohty M. 2019
12 108 10.1186/s13045-019-0790-x 10.1186/s13045-019-0790-x
Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT Bone Marrow Transplant Cahu X. Labopin M. Giebel S. Aljurf M. Kyrcz-Krzemien S. Socié G. Eder M. Bonifazi F. Bunjes D. Vigouroux S. Michallet M. Stelljes M. Zuckerman T. Finke J. Passweg J. Yakoub-Agha I. Niederwieser D. Sucak G. Sengeløv H. Polge E. Nagler A. Esteve J. Mohty M. Acute Leukemia Working Party of EBMT 2016
51 351 357 10.1038/bmt.2015.278 10.1038/bmt.2015.278 26618548
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study J Clin Oncol Peters C. Dalle J. H. Locatelli F. Poetschger U. Sedlacek P. Buechner J. Shaw P. J. Staciuk R. Ifversen M. Pichler H. Vettenranta K. Svec P. Aleinikova O. Stein J. Güngör T. Toporski J. Truong T. H. Diaz-de-Heredia C. Bierings M. Ariffin H. Essa M. Burkhardt B. Schultz K. Meisel R. Lankester A. Ansari M. Schrappe M. von Stackelberg A. Balduzzi A. Corbacioglu S. Bader P. 2021
39 295 307 10.1200/JCO.20.02529 10.1200/JCO.20.02529 33332189
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial J Clin Oncol Zhang H. Fan Z. Huang F. Han L. Xu Y. Xu N. Deng L. Wang S. Lin D. Luo X. Zhang Q. Liu X. Li X. Liang X. Xie S. Qu H. Yu S. Zhou H. Shi P. Xuan L. Lin R. Liu H. Jin H. Sun J. Liu Q. 2023
41 343 353 10.1200/JCO.22.00767 10.1200/JCO.22.00767 36084276
Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT Cancer Czerw T. Labopin M. Giebel S. Socié G. Volin L. Fegueux N. Masszi T. Blaise D. Chaganti S. Cornelissen J. J. Passweg J. Maertens J. Itälä-Remes M. Wu D. Mohty M. Nagler A. 2018
124 2523 2533 10.1002/cncr.31354 10.1002/cncr.31354 29603136
Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT Eur J Cancer Giebel S. Labopin M. Czerw T. Socié G. Blaise D. Ghavamzadeh A. Passweg J. Ljungman P. Poiré X. Chevallier P. Reményi P. Rambaldi A. Anafasyev B. Fegueux N. Rovira M. Itälä-Remes M. Bornhäuser M. Mohty M. Nagler A. 2019
106 212 219 10.1016/j.ejca.2018.11.003 10.1016/j.ejca.2018.11.003 30528805
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia N Engl J Med Maude S.L. Laetsch T.W. Buechner J. Rives S. Boyer M. Bittencourt H. Bader P. Verneris M.R. Stefanski H.E. Myers G.D. Qayed M. De Moerloose B. Hiramatsu H. Schlis K. Davis K.L. Martin P.L. Nemecek E.R. Yanik G.A. Peters C. Baruchel A. Boissel N. Mechinaud F. Balduzzi A. Krueger J. June C.H. Levine B.L. Wood P. Taran T. Leung M. Mueller K.T. Zhang Y. Sen K. Lebwohl D. Pulsipher M.A. Grupp S.A. 2018
378 439 448 10.1056/NEJMoa1709866 10.1056/NEJMoa1709866 29385370
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Lancet Shah B. D. Ghobadi A. Oluwole O. O. Logan A. C. Boissel N. Cassaday R. D. Leguay T. Bishop M. R. Topp M. S. Tzachanis D. O'Dwyer K. M. Arellano M. L. Lin Y. Baer M. R. Schiller G. J. Park J. H. Subklewe M. Abedi M. Minnema M. C. Wierda W. G. DeAngelo D. J. Stiff P. Jeyakumar D. Feng C. Dong J. Shen T. Milletti F. Rossi J. M. Vezan R. Masouleh B. K. Houot R. 2021
398 491 502 10.1016/S0140-6736(21)01222-8 10.1016/S0140-6736(21)01222-8 34097852
Next generations of CAR-T cells - new therapeutic opportunities in hematology? Front Immunol Tomasik J. Jasiński M. Basak G. W. 2022
13 2022 1034707 10.3389/fimmu.2022.1034707 10.3389/fimmu.2022.1034707 36389658
Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies Hematol Oncol Stem Cell Ther Yang Y. Bi X. Gergis M. Yi D. Hsu J. Gergis U. 2022
15 112 116 10.56875/2589-0646.1030 10.56875/2589-0646.1030 36537911
